Complete Guide to Patritumab Deruxtecan (HER3-DXd) Pharmacokinetics
Overview
Patritumab Deruxtecan (HER3-DXd) is a Antibody-Drug Conjugate (ADC) used in the Oncology / NSCLC therapeutic area. It is indicated for EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload. Population PK simulator for patritumab deruxtecan (HER3-DXd) — HER3-directed ADC with DXd payload for EGFR-mutant NSCLC. Two-compartment ADC model with body-weight covariate (exponent 0.72) linked to one-compartment DXd payload. Standard dose 5.6 mg/kg Q3W. Based on Guo et al. 2024 CPT:PSP. Compare DXd payload exposure vs T-DXd and Dato-DXd.
Mechanism of Action
Patritumab Deruxtecan (HER3-DXd) exerts its pharmacological effect by targeting HER3 (ERBB3). As a Antibody-Drug Conjugate (ADC), it modulates this target to achieve therapeutic efficacy in EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published Population PK (2-CMT ADC + 1-CMT DXd Payload) models for Patritumab Deruxtecan (HER3-DXd):
| Parameter | Value |
|---|---|
| k12 | 0.18 |
| k21 | 0.28 |
| ADC CL | 0.38 |
| DXd Vd | 580 |
| Standard Dose | 5.6 |
| DXd Payload CL | 45 |
| ADC V1 (Central) | 3.2 |
| BW Exponent on CL | 0.72 |
| ADC V2 (Peripheral) | 1.8 |
| Payload Release Rate (kr) | 0.012 |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Patritumab Deruxtecan (HER3-DXd) is administered via the IV Infusion route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology / NSCLC therapeutic area, for the treatment of EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload, understanding the pharmacokinetics of Patritumab Deruxtecan (HER3-DXd) is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Patritumab Deruxtecan (HER3-DXd) pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
- •Anti-drug antibody (ADA) formation and immunogenicity
Interactive Patritumab Deruxtecan (HER3-DXd) PK Simulator
Explore Patritumab Deruxtecan (HER3-DXd) pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Patritumab Deruxtecan (HER3-DXd)?
The elimination half-life of Patritumab Deruxtecan (HER3-DXd) depends on patient-specific factors. Use our interactive Patritumab Deruxtecan (HER3-DXd) PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Patritumab Deruxtecan (HER3-DXd) administered?
Patritumab Deruxtecan (HER3-DXd) is administered via the IV Infusion route. It is indicated for EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload. As a Antibody-Drug Conjugate (ADC), dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Patritumab Deruxtecan (HER3-DXd)?
Key pharmacokinetic parameters for Patritumab Deruxtecan (HER3-DXd) include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Patritumab Deruxtecan (HER3-DXd) dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Patritumab Deruxtecan (HER3-DXd) PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.